In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancer Factors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expression Determining the need for adjuvant chemotherapy and selection of chemotherapy agents Selection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapy Potential use of preoperative CDK4/6 inhibitors Sequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutation Overview of first-line therapy for advanced HR+/HER2 breast cancer Expert opinion on selection of first-line therapy and factors to consider Selection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trial Presenters: Joyce O’Shaughnessy, MD Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Chair, Breast Disease Committee Sarah Cannon Research Institute Texas Oncology Dallas, Texas Sara A. Hurvitz, MD, FACP Professor of Medicine Head, Division of Hematology and Oncology Department of Medicine, UW Medicine Senior Vice President Clinical Research Division Fred Hutchinson Cancer Center Seattle, Washington Erica L. Mayer, MD, MPH Director of Breast Cancer Clinical Research Institute Physician Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Link to full program: https://bit.ly/3XZKp8f Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
